BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23751561)

  • 21. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
    Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
    Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
    Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
    Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase induces receptor mediated brain tumor cell migration and invasion.
    MacDonald TJ; DeClerck YA; Laug WE
    J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
    Okada SS; Grobmyer SR; Barnathan ES
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
    Lee SB; Oh HK; Kim HK; Joe YA
    Protein Expr Purif; 2006 Nov; 50(1):1-8. PubMed ID: 16854593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
    Guo Y; Higazi AA; Arakelian A; Sachais BS; Cines D; Goldfarb RH; Jones TR; Kwaan H; Mazar AP; Rabbani SA
    FASEB J; 2000 Jul; 14(10):1400-10. PubMed ID: 10877833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel tumor targeting drug carrier for optical imaging and therapy.
    Li R; Zheng K; Hu P; Chen Z; Zhou S; Chen J; Yuan C; Chen S; Zheng W; Ma E; Zhang F; Xue J; Chen X; Huang M
    Theranostics; 2014; 4(6):642-59. PubMed ID: 24723985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification and characterization of recombinant murine endostatin in E. coli.
    You WK; So SH; Lee H; Park SY; Yoon MR; Chang SI; Kim HK; Joe YA; Hong YK; Chung SI
    Exp Mol Med; 1999 Dec; 31(4):197-202. PubMed ID: 10630374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
    Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
    Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
    Wang X; Hou M; Tan L; Sun X; Zhang Y; Li P; Zhu Y
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):129-36. PubMed ID: 15490235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Endothelial genesis inhibitor-8t (EDI-8t) against tumor growth].
    Zhou Q; Du P; Qian Y; Zhang Q; Feng B; Ding H; Gan R; Zhang H
    Sheng Wu Gong Cheng Xue Bao; 2010 Dec; 26(12):1724-31. PubMed ID: 21387837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo.
    Kunimasa K; Ikekita M; Sato M; Ohta T; Yamori Y; Ikeda M; Kuranuki S; Oikawa T
    Cancer Sci; 2010 Nov; 101(11):2462-9. PubMed ID: 20670297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
    Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
    Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.